Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...
The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
News Medical on MSN11d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders. HealthDay News — For people with diabetes, the use of glucagon-like ...
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback